Visit COVID-19 resources

[Skip to Content]

Age-related Macular Degeneration

Age-related Macular Degeneration (AMD) is a long term condition which is the leading cause of sight loss in the UK. Sight loss often occurs quickly with the exudative (“wet”) form of AMD but can be stabilised or improved in most cases with prompt treatment and timely monitoring. The main objective for an AMD service is to minimise preventable sight loss.

Guidance Description
Commissioning better eye care: Age-related macular degeneration – 2013 Commissioning better eye care: Age-related macular degeneration from The College of Optometrists and The Royal College of Ophthalmologists is to help those designing and commissioning eye care to improve the value of their services.
SAFE – Age-related Macular Degeneration – 2017 Developed by the Clinical Council for Eye Health Commissioning (CCEHC), SAFE (Systems and Assurance Framework for Eye health) provides the tools to help commissioners in developing a more strategic and consistent approach to planning and delivering services.

This SAFE documents focuses on Age-related Macular Degeneration (AMD)


Intravitreal Injection Therapy

The Way Forward AMD Summary

The Way Forward AMD Report

Commissioning better eye care: Age-related macular degeneration

Choice of anti VEGF agents for wet AMD treatments

Maximising Capacity in AMD Services

New to follow up ratios in ophthalmology outpatient services

Quality Standard for Medical Retina Disease Services

Want more information?